These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 10463079)

  • 1. An antisense oligonucleotide primer.
    Hogrefe RI
    Antisense Nucleic Acid Drug Dev; 1999 Aug; 9(4):351-7. PubMed ID: 10463079
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic applications of antisense oligonucleotides in asthma and allergy.
    Isidoro-García M; Dávila I
    Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):171-5. PubMed ID: 19075979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential for transcatheter application of antisense oligonucleotides for the treatment of vascular diseases.
    Morishita R; Gibbons GH; Dzau VJ
    J Interv Cardiol; 1995 Aug; 8(4):377-81. PubMed ID: 10155251
    [No Abstract]   [Full Text] [Related]  

  • 4. The macrophage as a Trojan horse for antisense oligonucleotide delivery.
    Novak JS; Jaiswal JK; Partridge TA
    Expert Opin Ther Targets; 2018 Jun; 22(6):463-466. PubMed ID: 29860876
    [No Abstract]   [Full Text] [Related]  

  • 5. Antisense oligonucleotides in cancer.
    Castanotto D; Stein CA
    Curr Opin Oncol; 2014 Nov; 26(6):584-9. PubMed ID: 25188471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Making sense of antisense.
    Murakami A
    Trends Mol Med; 2001 Oct; 7(10):430-1. PubMed ID: 11597507
    [No Abstract]   [Full Text] [Related]  

  • 7. Cyclodextrins and oligonucleotide delivery to solid tumours.
    Dass CR
    J Drug Target; 2004 Jan; 12(1):1-9. PubMed ID: 15203906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense oligonucleotide therapy in the management of bladder cancer.
    So A; Rocchi P; Gleave M
    Curr Opin Urol; 2005 Sep; 15(5):320-7. PubMed ID: 16093856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Facilitating oligonucleotide delivery: helping antisense deliver on its promise.
    Gewirtz AM; Stein CA; Glazer PM
    Proc Natl Acad Sci U S A; 1996 Apr; 93(8):3161-3. PubMed ID: 8622906
    [No Abstract]   [Full Text] [Related]  

  • 10. [Molecular therapy for vascular disease using an oligonucleotide-based strategy].
    Miyake T; Morishita R
    Nihon Yakurigaku Zasshi; 2007 Mar; 129(3):158-62. PubMed ID: 17379964
    [No Abstract]   [Full Text] [Related]  

  • 11. Antisense therapeutics.
    Holt J
    Mol Med Today; 1996 May; 2(5):184-5. PubMed ID: 8796885
    [No Abstract]   [Full Text] [Related]  

  • 12. Oligonucleotide-based gene therapy for cardiovascular disease.
    Morishita R; Nakagami H; Taniyama Y; Matsushita H; Yamamoto K; Tomita N; Moriguchi A; Matsumoto K; Higaki J; Ogihara T
    Clin Chem Lab Med; 1998 Aug; 36(8):529-34. PubMed ID: 9806454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antisense nucleic acids and gene therapy].
    Saison-Behmoaras E
    Bull Cancer; 1995 Mar; 82(3):224-5. PubMed ID: 7655155
    [No Abstract]   [Full Text] [Related]  

  • 14. Less is more: therapeutic exon skipping for Duchenne muscular dystrophy.
    Aartsma-Rus A; van Ommen GJ
    Lancet Neurol; 2009 Oct; 8(10):873-5. PubMed ID: 19713153
    [No Abstract]   [Full Text] [Related]  

  • 15. Antisense technologies have a future fighting neurodegenerative diseases.
    Seidman S; Eckstein F; Grifman M; Soreq H
    Antisense Nucleic Acid Drug Dev; 1999 Aug; 9(4):333-40. PubMed ID: 10463077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides.
    Dirin M; Winkler J
    Expert Opin Biol Ther; 2013 Jun; 13(6):875-88. PubMed ID: 23451977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery of anti-microRNA-21 antisense-oligodeoxynucleotide using amphiphilic peptides for glioblastoma gene therapy.
    Song H; Oh B; Choi M; Oh J; Lee M
    J Drug Target; 2015 May; 23(4):360-70. PubMed ID: 25572456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense oligonucleotide technology: from EST to therapeutics.
    Giles RV
    Curr Opin Mol Ther; 2000 Jun; 2(3):238-52. PubMed ID: 11249617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in antisense research and development.
    Thierry AR; Bradley MO; Chrisey LA
    Antisense Res Dev; 1993; 3(4):411-6. PubMed ID: 8155983
    [No Abstract]   [Full Text] [Related]  

  • 20. Oligonucleotide therapeutics: a step forward.
    Gewirtz AM
    J Clin Oncol; 2000 May; 18(9):1809-11. PubMed ID: 10784620
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.